Australia seems poised to experience innovative treatment for weight issues: Retatrutide. This dual agonist – working on both GLP-1 and GIP receptors – has promising outcomes in clinical research, suggesting considerable decreases in weight. While availability hasn't occurred with Australian regulators, a number of people dealing with being ove